Bayer: Annual Report 2013 (Bayer AG) - Mar 1, 2014 - Anticipated expiry of active ingredient patent in Canada in 2019; Anticipated expiry of formulation patents in Germany, France, UK, Italy and Spain in 2017; Anticipated expiry of formulation patent in Japan in 2017; Anticipated expiry of formulation patent in China in 2017; Anticipated expiry of formulation patent in US in 2017; Anticipated expiry of formulation patent in Canada in 2017; Anticipated expiry of active ingredient patent in US in 2014
Anticipated patent expiry • Hemophilia
|